A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• FMS-like tyrosine kinase 3 (FLT3) mutations, particularly internal tandem duplications (ITD) and tyrosine kinase domain (TKD) mutations, are common in acute myeloid leukemia (AML) and linked to poor prognosis.
• Acquired resistance mutations, such as the gatekeeper mutation F691L in the FLT3-TKD, limit the efficacy of current FLT3 inhibitors.
• There is an urgent need for novel FLT3 inhibitors that can overcome these resistance mechanisms.

Discussion:

• KX2-391 demonstrates potent anti-leukemic activity against diverse AML cell lines harboring FLT3-ITD and drug-resistant FLT3-TKD mutations (D835, F691L).
• The drug inhibits FLT3 phosphorylation and downstream signaling pathways crucial for leukemia cell survival and proliferation.
• KX2-391 exhibits efficacy in preclinical models, including oral administration in a murine model of FLT3-ITD-F691L leukemia and inhibition of primary AML cells.

Key Insights:

• KX2-391 acts as a dual inhibitor of FLT3 and tubulin, offering a unique mechanism of action.
• It effectively overcomes resistance mediated by specific FLT3-TKD mutations, including the F691L gatekeeper mutation.
• Preclinical data strongly support KX2-391's potential as a therapeutic agent for FLT3-mutated AML.

Outlook:

• KX2-391 represents a promising candidate for clinical development in AML patients with FLT3 mutations.
• Further investigation is warranted to evaluate its safety and efficacy in refractory/relapsed AML populations.
• This dual inhibitor may offer a new therapeutic strategy for overcoming treatment resistance in FLT3-mutated leukemias.